| scholarly article | Q13442814 |
| P50 | author | Shakil Ahmad | Q43177725 |
| P2093 | author name string | Asif Ahmed | |
| Yang Xia | |||
| Rodney E Kellems | |||
| Peter W Hewett | |||
| Shahrzad Abbasi | |||
| ChunXiao Sun | |||
| Cissy Chenyi Zhou | |||
| Lingwei Xia | |||
| TieJuan Mi | |||
| P2860 | cites work | Effects of cyclosporin A, FK506 and rapamycin on calcineurin phosphatase activity in mouse brain | Q48487264 |
| A novel gene (Cmya3) induced in the heart by angiotensin II-dependent but not salt-dependent hypertension in mice | Q48637388 | ||
| Urinary Placental Growth Factor and Risk of Preeclampsia | Q56619498 | ||
| Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with Preeclampsia | Q56619500 | ||
| Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor | Q56619503 | ||
| A Vascular Endothelial Growth Factor Antagonist Is Produced by the Human Placenta and Released into the Maternal Circulation1 | Q61479346 | ||
| Analysis of changes in the renin-angiotensin system during pregnancy | Q68640705 | ||
| Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR | Q71530460 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Pregnancy-induced changes in renin gene expression in mice | Q77372149 | ||
| Placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia | Q80553904 | ||
| Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop | Q80914460 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor | Q24320710 | ||
| Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? | Q24561702 | ||
| Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide | Q28350767 | ||
| Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice | Q28504776 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Serial analysis of gene expression in mouse kidney following angiotensin II administration | Q33194116 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. | Q33930029 | ||
| A study of angiotensin II pressor response throughout primigravid pregnancy | Q34512573 | ||
| Physiology of local renin-angiotensin systems. | Q34543927 | ||
| Trophoblast expression of fms-like tyrosine kinase 1 is not required for the establishment of the maternal-fetal interface in the mouse placenta | Q34790007 | ||
| Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome | Q35750283 | ||
| Localization of the angiotensin II and its receptor subtype expression in human endometrium and identification of a novel high-affinity angiotensin II binding site | Q35752519 | ||
| Transgenic mice for studies of the renin-angiotensin system in hypertension. | Q35850586 | ||
| Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question | Q35920602 | ||
| New insights into the biology of preeclampsia | Q36371864 | ||
| Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. Angiotensin II stimulates the release of vasorelaxants | Q37377636 | ||
| Gene expression profiling of potential PPARgamma target genes in mouse aorta | Q38342990 | ||
| The renin-angiotensin system in pregnancy and parturition | Q39587865 | ||
| Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia | Q40530224 | ||
| A quantitative real-time PCR method for tissue factor mRNA. | Q40589336 | ||
| Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation | Q40735093 | ||
| Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta | Q41385756 | ||
| The immunosuppressive drugs cyclosporin A and FK506 inhibit calcineurin phosphatase activity and gene transcription mediated through the cAMP-responsive element in a nonimmune cell line | Q41519362 | ||
| In vivo rat model of preeclampsia | Q44271036 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation | Q45069619 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta | Q47849467 | ||
| Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia | Q47915288 | ||
| The human placental renin-angiotensin system | Q48430627 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 88-95 | |
| P577 | publication date | 2006-12-07 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | |
| P478 | volume | 100 |
| Q37132801 | AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia |
| Q38118625 | Activating autoantibodies and cardiovascular disease |
| Q36526596 | Angiogenic factors in preeclampsia and related disorders |
| Q34341543 | Angiotensin II and angiotensin-(1-7) decrease sFlt1 release in normal but not preeclamptic chorionic villi: an in vitro study |
| Q37353499 | Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension |
| Q35701236 | Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice |
| Q33748680 | Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity |
| Q24605647 | Angiotensin receptors, autoimmunity, and preeclampsia |
| Q48189809 | Anti-Interleukin-22-Neutralizing Antibody Attenuates Angiotensin II-Induced Cardiac Hypertrophy in Mice. |
| Q37307973 | Are we getting closer to a Nobel prize for unraveling preeclampsia? |
| Q54506654 | Association between von Willebrand factor gene polymorphism and preeclampsia. |
| Q50077615 | Autoantibodies against angiotensin and adrenergic receptors: more than a biomarker? |
| Q35681804 | Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling |
| Q35715914 | Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia |
| Q36050771 | Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling |
| Q38426343 | Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. |
| Q33789436 | B cells: the old new players in reproductive immunology |
| Q36339273 | Blockade of CD40 ligand for intercellular communication reduces hypertension, placental oxidative stress, and AT1-AA in response to adoptive transfer of CD4+ T lymphocytes from RUPP rats |
| Q36528002 | Control of soluble fms-like tyrosine-1 (sFlt-1) production response to placental ischemia/hypoxia: role of tumor necrosis factor-α. |
| Q34731047 | Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia |
| Q93109012 | Disturbed Cardiorespiratory Adaptation in Preeclampsia: Return to Normal Stress Regulation Shortly after Delivery? |
| Q37454990 | Elevated ecto-5'-nucleotidase-mediated increased renal adenosine signaling via A2B adenosine receptor contributes to chronic hypertension |
| Q35140024 | Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications |
| Q34655258 | First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia |
| Q38056887 | From preeclampsia to renal disease: a role of angiogenic factors and the renin-angiotensin aldosterone system? |
| Q35918271 | Human placental expression of SLIT/ROBO signaling cues: effects of preeclampsia and hypoxia |
| Q35029700 | Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes |
| Q91842370 | Increased LIGHT leading to sFlt-1 elevation underlies the pathogenic link between hydatidiform mole and preeclampsia |
| Q33893203 | Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy |
| Q37119326 | Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia |
| Q48641988 | Interleukin 22 Promotes Blood Pressure Elevation and Endothelial Dysfunction in Angiotensin II-Treated Mice |
| Q37346569 | Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage |
| Q36241932 | International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. |
| Q36050775 | Is preeclampsia an autoimmune disease? |
| Q90106114 | Letter to the Editor: Importance of B cells in response to placental ischemia |
| Q58911048 | Molecular mechanisms of preeclampsia |
| Q37024446 | Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. |
| Q38017497 | Pathogenesis of pre-eclampsia: marinobufagenin and angiogenic imbalance as biomarkers of the syndrome |
| Q37022723 | Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction |
| Q24649934 | Pathophysiology of placentation abnormalities in pregnancy-induced hypertension |
| Q35045834 | Placenta-specific miRNA (miR-512-3p) targets PPP3R1 encoding the calcineurin B regulatory subunit in BeWo cells |
| Q64226376 | Placental CX3CL1 is Deregulated by Angiotensin II and Contributes to a Pro-Inflammatory Trophoblast-Monocyte Interaction |
| Q54256280 | Placental Regulation of Inflammation and Hypoxia after TNF-α Infusion in Mice. |
| Q37114991 | Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections |
| Q34908922 | Placentation abnormalities in the pathophysiology of preeclampsia |
| Q35681821 | Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia |
| Q37362662 | Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection |
| Q36965155 | Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines |
| Q37879823 | Pregnancy-associated homeostasis and dysregulation: lessons from genetically modified animal models |
| Q35683468 | Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice |
| Q35363716 | Regulation of soluble fms-like tyrosine kinase-1 production in response to placental ischemia/hypoxia: role of angiotensin II. |
| Q57254079 | Regulator of G protein signaling 5 is a determinant of gestational hypertension and preeclampsia |
| Q33411571 | Renal function in normal and disordered pregnancy |
| Q35743816 | Renin angiotensin signaling in normal pregnancy and preeclampsia |
| Q64907090 | Renin-angiotensin system in pre-eclampsia: everything old is new again. |
| Q47923741 | Renin-angiotensin system transgenic mouse model recapitulates pathophysiology similar to human preeclampsia with renal injury that may be mediated through VEGF. |
| Q90248296 | Role of the NLRP3 Inflammasome in Preeclampsia |
| Q34169819 | Targeted expression of Cre recombinase provokes placental-specific DNA recombination in transgenic mice |
| Q33591058 | The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia |
| Q37039872 | The functional role of the renin-angiotensin system in pregnancy and preeclampsia |
| Q26798193 | The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia |
| Q37041658 | The role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: early- versus late-onset pre-eclampsia |
| Q54495054 | The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. |
| Q38116097 | Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. |
Search more.